yahoo_financeOriginal article
MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial
Phase 2positiveTHIO-101Positive
AI Analysis
Summary
MAIA Biotechnology reported strong initial efficacy data from the Phase 2 THIO-101 Part C expansion trial in third-line non-small cell lung cancer. The positive data readout supports further development of the candidate.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
Strong initial efficacy data
Importance:6/10
Sentiment:
0.75
Phase 2Efficacy DataLung CancerOncology
Related Companies
Read the original article
Published by yahoo_finance on July 8, 2026 1:45 PM